Viva Biotech is the fourth largest company in China’s drug discovery services industry, with a 2.6 per cent market share. Photo: Bloomberg

Investors pile into Viva Biotech’s Hong Kong IPO as they are confident of the R&D services provider’s business model

  • Not only is the firm profit-making, but its investment in potential drug candidates has made it attractive to investors, says Louis Tse Ming Kwong of VC Asset Management
  • Viva’s business model of taking equity in smaller companies is a convenient way of having many shots on a goal in the Asian biotech, says Brad Loncar of Loncar Investments
Topic |   Health & Fitness

TOP PICKS

Viva Biotech is the fourth largest company in China’s drug discovery services industry, with a 2.6 per cent market share. Photo: Bloomberg
READ FULL ARTICLE